India Exchange Filings

Wanbury Investor Query Clarifications

Wanbury Ltd says operations and FY27 guidance remain unaffected, with Tanuku’s US-market exposure at ~6% of consolidated YTD revenue

  • Tanuku facility’s US-market exposure remains unaffected.
  • New ANDAs and filings will be handled by the US FDA-approved Patalganga facility.
  • The company said its assessment of operations and FY27 guidance is unchanged.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.